Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Orbio Corporation manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is being reviewed by 1 distinct examiner and is situated within 1 distinct art unit. This indicates a singular focus for the company's current patent office interactions. For a practitioner, this means that the prosecution outcome for the pending matter depends entirely on the specific practices of this 1 distinct examiner and the 1 distinct art unit involved.
The busiest examiner for this portfolio is BERRY, LAYLA D, who is assigned 1 busiest examiner pending action. Because there is only 1 pending office action in total, BERRY, LAYLA D is the only examiner currently engaged with the portfolio. This concentrated activity allows for a very specific focus on the requirements and preferences of a single reviewer within the Biotechnology & Pharmaceuticals sector. The absence of multiple pending actions simplifies the monitoring process but increases the impact of individual examiner tendencies on the overall portfolio. Practitioners must carefully address the specific standards of the 1 distinct art unit to advance the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698654 | GLUCOSE DERIVATIVES AND ANTICANCER AGENT USING SAME | BERRY, LAYLA D | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698654 | GLUCOSE DERIVATIVES AND ANTICANCER AGENT USING SAME | BERRY, LAYLA D | 1693 | §102§103§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrbio Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla D Berry has the most, with 1 of Orbio Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
